Bile acids as emerging players at the intersection of steatotic liver disease and cardiovascular diseases
Bile acids as emerging players at the intersection of steatotic liver disease and cardiovascular diseases
Affecting approximately 25% of the global population, steatotic liver disease (SLD) poses a significant health concern. SLD ranges from simple steatosis to metabolic dysfunction-associated steatohepatitis and fibrosis with a risk of severe liver complications such as cirrhosis and hepatocellular carcinoma. SLD is associated with obesity, atherogenic dyslipidaemia, and insulin resistance, increasing cardiovascular risks. As such, identifying SLD is vital for cardiovascular disease (CVD) prevention and treatment. Bile acids (BAs) have critical roles in lipid digestion and are signalling molecules regulating glucose and lipid metabolism and influencing gut microbiota balance. BAs have been identified as critical mediators in cardiovascular health, influencing vascular tone, cholesterol homeostasis, and inflammatory responses. The cardio-protective or harmful effects of BAs depend on their concentration and composition in circulation. The effects of certain BAs occur through the activation of a group of receptors, which reduce atherosclerosis and modulate cardiac functions. Thus, manipulating BA receptors could offer new avenues for treating not only liver diseases but also CVDs linked to metabolic dysfunctions. In conclusion, this review discusses the intricate interplay between BAs, metabolic pathways, and hepatic and extrahepatic diseases. We also highlight the necessity for further research to improve our understanding of how modifying BA characteristics affects or ameliorates disease.
bile acid receptors, bile acids, cardiac disease, cardiovascular disease, farnesoid X receptor, metabolic dysfunction-associated steatotic liver disease, obeticholic acid, resmetirom
Bilson, Josh
a99f9320-335c-47c8-bf30-07df48a5467d
Scorletti, Eleonora
4e896544-2974-4f81-9696-1595d3c36814
Swann, Jonathan
7c11a66b-f4b8-4dbf-aa17-ad8b0561b85c
Byrne, Chris
1370b997-cead-4229-83a7-53301ed2a43c
12 July 2024
Bilson, Josh
a99f9320-335c-47c8-bf30-07df48a5467d
Scorletti, Eleonora
4e896544-2974-4f81-9696-1595d3c36814
Swann, Jonathan
7c11a66b-f4b8-4dbf-aa17-ad8b0561b85c
Byrne, Chris
1370b997-cead-4229-83a7-53301ed2a43c
Bilson, Josh, Scorletti, Eleonora, Swann, Jonathan and Byrne, Chris
(2024)
Bile acids as emerging players at the intersection of steatotic liver disease and cardiovascular diseases.
Biomolecules, 14 (7), [841].
(doi:10.3390/biom14070841).
Abstract
Affecting approximately 25% of the global population, steatotic liver disease (SLD) poses a significant health concern. SLD ranges from simple steatosis to metabolic dysfunction-associated steatohepatitis and fibrosis with a risk of severe liver complications such as cirrhosis and hepatocellular carcinoma. SLD is associated with obesity, atherogenic dyslipidaemia, and insulin resistance, increasing cardiovascular risks. As such, identifying SLD is vital for cardiovascular disease (CVD) prevention and treatment. Bile acids (BAs) have critical roles in lipid digestion and are signalling molecules regulating glucose and lipid metabolism and influencing gut microbiota balance. BAs have been identified as critical mediators in cardiovascular health, influencing vascular tone, cholesterol homeostasis, and inflammatory responses. The cardio-protective or harmful effects of BAs depend on their concentration and composition in circulation. The effects of certain BAs occur through the activation of a group of receptors, which reduce atherosclerosis and modulate cardiac functions. Thus, manipulating BA receptors could offer new avenues for treating not only liver diseases but also CVDs linked to metabolic dysfunctions. In conclusion, this review discusses the intricate interplay between BAs, metabolic pathways, and hepatic and extrahepatic diseases. We also highlight the necessity for further research to improve our understanding of how modifying BA characteristics affects or ameliorates disease.
Text
biomolecules-3107810_JB
- Accepted Manuscript
Text
20240627_Supplementary_material_Biomolecules
- Accepted Manuscript
Text
biomolecules-14-00841-v2
- Version of Record
More information
Accepted/In Press date: 10 July 2024
Published date: 12 July 2024
Additional Information:
Please check journal regulations for embargo timeline/restrictions. Many thanks
Keywords:
bile acid receptors, bile acids, cardiac disease, cardiovascular disease, farnesoid X receptor, metabolic dysfunction-associated steatotic liver disease, obeticholic acid, resmetirom
Identifiers
Local EPrints ID: 492147
URI: http://eprints.soton.ac.uk/id/eprint/492147
PURE UUID: bf2cc448-8554-4dcf-9f5a-e304d7cca28c
Catalogue record
Date deposited: 18 Jul 2024 16:32
Last modified: 10 Aug 2024 02:06
Export record
Altmetrics
Contributors
Author:
Josh Bilson
Author:
Eleonora Scorletti
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics